Prostate cancer

You have access
Low Body Weight as a Risk Factor for Apalutamide-related Cutaneous Adverse Events
MICHIE KATSUTA, TAKAHIRO KIMURA, KOJIRO TASHIRO, MASAYA MURAKAMI, KENICHI HATA, TAKAFUMI YANAGISAWA, HAJIME ONUMA, TOSHIHIRO YAMAMOTO, SHINGO SUGAYA, YOSHINORI WATANABE, YOSHIMASA NOBEYAMA, SHIN EGAWA and AKIHIKO ASAHINA

Anticancer Research April 2022, 42 (4) 2023-2028; DOI: https://doi.org/10.21873/anticanres.15682
You have access
Treatment Outcomes in Neuroendocrine Prostate Cancer
HIROAKI IWAMOTO, RYUNOSUKE NAKAGAWA, TOMOYUKI MAKINO, SUGURU KADOMOTO, HIROSHI YAEGASHI, TAKAHIRO NOHARA, KAZUYOSHI SHIGEHARA, KOUJI IZUMI, YOSHIFUMI KADONO and ATSUSHI MIZOKAMI

Anticancer Research April 2022, 42 (4) 2167-2176; DOI: https://doi.org/10.21873/anticanres.15699
You have access
Should 68Ga-PSMA PET/CT Replace CT and Bone Scan in Clinical Staging of High-risk Prostate Cancer?
PIETRO PEPE and MICHELE PENNISI

Anticancer Research March 2022, 42 (3) 1495-1498; DOI: https://doi.org/10.21873/anticanres.15621
You have access
Kindlin-3 in Immune Cells Is Required to Suppress Prostate Cancer Tumor Growth in Mice
CHENG LIU, YING ZHOU, YU ZHOU, ZHEN XU and YAN-QING MA

Anticancer Research March 2022, 42 (3) 1217-1220; DOI: https://doi.org/10.21873/anticanres.15588
You have access
Prognostic Significance of 3-Month Prostate-specific Antigen Level Following Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer
YUJIRO NAGATA, TAKUO MATSUKAWA, IKKO TOMISAKI and NAOHIRO FUJIMOTO

Anticancer Research February 2022, 42 (2) 1107-1114; DOI: https://doi.org/10.21873/anticanres.15573
You have access
The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer
ROBERTO IACOVELLI, CHIARA CICCARESE, ORAZIO CAFFO, UGO DE GIORGI, UMBERTO BASSO, MARCELLO TUCCI, CLAUDIA MOSILLO, MARCO MARUZZO, FRANCESCA MAINES, CHIARA CASADEI, MICHELE MILELLA and GIAMPAOLO TORTORA

Anticancer Research January 2022, 42 (1) 165-172; DOI: https://doi.org/10.21873/anticanres.15470
You have access
Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study
MIIKKA LEHTONEN, JORMA SORMUNEN, MARIE HJÄLM-ERIKSSON, CAMILLA THELLENBERG-KARLSSON, TEPPO HUTTUNEN, CLAES GINMAN, PIRKKO-LIISA KELLOKUMPU-LEHTINEN and On Behalf of the Investigators of the Scandinavian Prostate Cancer Group Study No 13

Anticancer Research January 2022, 42 (1) 87-92; DOI: https://doi.org/10.21873/anticanres.15460
You have access
Reduction in Copper Uptake and Inhibition of Prostate Cancer Cell Proliferation by Novel Steroid-based Compounds
FANG XIE and FANGYU PENG

Anticancer Research December 2021, 41 (12) 5953-5958; DOI: https://doi.org/10.21873/anticanres.15414
You have access
Inhibition of CYP27B1 and CYP24 Increases the Anti-proliferative Effects of 25-Hydroxyvitamin D₃ in LNCaP Cells
SANDRA KARLSSON, MARIA ARACELI DIAZ CRUZ, MARIA FARESJÖ, ATHANASIA PAPADOPOULOU KHAMOU and DENNIS LARSSON

Anticancer Research October 2021, 41 (10) 4733-4740; DOI: https://doi.org/10.21873/anticanres.15288
You have access
Kartogenin Inhibits Prostate Cancer Cell Growth Through Smad2 Activation and Decreases Androgen Receptor Nuclear Localization
MANABU TAKAI, KYOJIRO KAWAKAMI, YASUNORI FUJITA, TAKU KATO, DAIKI KATO, KOJI IINUMA, TAKUYA KOIE, MASAFUMI ITO and KOSUKE MIZUTANI

Anticancer Research October 2021, 41 (10) 4753-4759; DOI: https://doi.org/10.21873/anticanres.15290

Main menu

User menu

Search

Prostate cancer

Pages